Work

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra

Year: 2015

Type: conference-abstract

Abstract: Meeting abstracts The durability of anti-tumor responses observed in patients treated with antibodies blocking PD-1 has provided a central role for these drugs in melanoma therapeutics. Identifying predictive biomarkers to aid therapeutic decision making is critical for realizing the full potential

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p103

Authors: Jeffrey Weber, Alberto J Martinez, Heinrich Roder, Joanna Roder, Krista Meyer, Senait Asmellash, Julia Grigorieva, Maxim Tsypin, Carlos Oliveira, Arni Steingrimsson, Kevin Sayers, Antonella Bacchiocchi, Mario Sznol, Ruth Halaban, Harriet Kluger

Institutions: Moffitt Cancer Center, Yale University, Yale Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2189887292

Cites: 1

Cited by: 6

Related to: 10